Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Braftovi“
Suchtreffer
Begriffe & Kennungen
Braftovi · 4.8 · Colorectal cancer Encorafenib and cetuximab combination In patients treated with encorafenib 300 mg in combina
Eintrag öffnenBraftovi · 4.8 · Colorectal cancer Encorafenib and cetuximab combination In patients treated with encorafenib 300 mg in combina
Eintrag öffnenBraftovi · 4.8 · Colorectal cancer Encorafenib and cetuximab combination In the population treated with encorafenib 300 mg in c
Eintrag öffnenBraftovi · 4.8 · Colorectal cancer Encorafenib and cetuximab combination The incidence of increased transaminases in patients t
Eintrag öffnenBraftovi · 4.8 · Common Dermatitis Dermatitis Skin hyperpigmentation Erythema acneiform* acneiform* PPES Hyperkeratosis* Skin e
Eintrag öffnenBraftovi · 4.8 · Common Facial paresisc Dysgeusia* Dizziness* Dizziness* Dysgeusia Uncommo Facial paresisc n
Eintrag öffnenBraftovi · 4.8 · Common Upper respiratory tract infection* Sepsis* Investigations Gamma-glutamyl Blood creatine Lipase increase
Eintrag öffnenBraftovi · 4.8 · Cutaneous malignancies Cutaneous squamous cell carcinoma Melanoma and NSCLC In the Combo 450 ISP, cuSCC includ
Eintrag öffnenBraftovi · 4.8 · Dermatitis acneiform Melanoma and NSCLC Dermatitis acneiform was reported when encorafenib is used in combinat
Eintrag öffnenBraftovi · 4.8 · Dermatologic reactions Rash Melanoma and NSCLC In the Combo 450 ISP, rash occurred in 20.4% (76/372) of patien
Eintrag öffnenBraftovi · 4.8 · Description of selected adverse reactions
Eintrag öffnenBraftovi · 4.8 · Elderly Melanoma and NSCLC In patients treated with Combo 450 ISP (n = 372), 230 patients (61.8%) were <65 yea
Eintrag öffnenBraftovi · 4.8 · Encorafenib with cetuximab and FOLFOX combination In the pooled EC+FOLFOX population, diarrhoea was observed i
Eintrag öffnenBraftovi · 4.8 · Facial paresis Melanoma and NSCLC In the Combo 450 ISP, facial paresis occurred in 0.8% (3/372) of patients in
Eintrag öffnenBraftovi · 4.8 · Fatigue Melanoma and NSCLC In the Combo 450 ISP, fatigue occurred in 48.1% (179/372) of patients including Gra
Eintrag öffnenBraftovi · 4.8 · Gastrointestinal disorders Melanoma and NSCLC In the Combo 450 ISP, diarrhoea was observed in 41.7% (155/372)
Eintrag öffnenBraftovi · 4.8 · Gastrointestinal disorders were typically managed with standard therapy.
Eintrag öffnenBraftovi · 4.8 · Haemorrhage Melanoma and NSCLC Haemorrhagic events were observed in 16.7% (62/372) of patients in the Combo 45
Eintrag öffnenBraftovi · 4.8 · Headache Melanoma and NSCLC In the Combo 450 ISP, headache occurred in 18.8% (70/372) of patients, including G
Eintrag öffnenBraftovi · 4.8 · Hypertension Hypertension was reported when encorafenib was used in combination with binimetinib in melanoma a
Eintrag öffnen